Phaseline

Companies › Gemma Biotherapeutics

Gemma Biotherapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Metabolic and endocrine, Neurology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PBGM01
AAVhu68 viral vector delivering functional GLB1 gene
GLB1Phase 1GM1 GangliosidosisFeb 2028
GB221
Gene therapy delivering functional SMN1 gene via AAV vector to motor neurons
SMN1Phase 1Spinal Muscular Atrophy Type IDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04713475PBGM01Phase 1GM1 GangliosidosisMetabolic and endocrineFeb 2028
NCT07070999GB221Phase 1Spinal Muscular Atrophy Type INeurologyDec 2028

Targets

GLB1 (1) SMN1 (1)

Companies with the same targets

Novartis GeneCradle Lanyue Biotech (Hangzhou) Biocad Lantu Biopharma

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.